Capsule Summary Slidesets

Share

Program Content

Activities

  • CheckMate 8HW
    CheckMate 8HW: Interim Analysis of Phase III Trial of Nivolumab + Ipilimumab vs Nivolumab for MSI-H or dMMR mCRC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 04, 2025

    Expires: August 03, 2025

  • STARTER NET
    STARTER-NET: Phase III Study of Everolimus ± Lanreotide for Unresectable or Recurrent GEP-NET
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 04, 2025

    Expires: August 03, 2025

  • ACCELERATE
    ACCELERATE: Phase III Study of Adjuvant Chemotherapy ± Chemoradiation in Gallbladder Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 04, 2025

    Expires: August 03, 2025

  • Botensilimab and Balstilimab for MSS mCRC
    Botensilimab ± Balstilimab for Refractory Microsatellite-Stable Metastatic Colorectal Cancer Without Liver Metastases
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 04, 2025

    Expires: August 03, 2025

  • BREAKWATER
    BREAKWATER: Phase III Study of First-line Encorafenib + Cetuximab + Chemotherapy vs SoC for BRAF V600E–Mutant mCRC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 04, 2025

    Expires: August 03, 2025

  • MAIC of 177LuDOTATATE vs Sunitinib
    177Lu-DOTATATE vs Sunitinib as Initial Treatment for Advanced Grade 2 Pancreatic Neuroendocrine Tumors Using Matching-Adjusted Indirect Comparison
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 05, 2025

    Expires: August 04, 2025

  • CABINET Subgroup Analysis
    CABINET: Subgroup Analysis of Cabozantinib vs Placebo After ≥1 Prior Line of Therapy in Advanced Extrapancreatic Neuroendocrine Tumors Arising in GI Tract
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 07, 2025

    Expires: August 06, 2025

  • WW vs TME After TNT for Rectal Cancer
    CAO/ARO/AIO-12 and OPRA: Pooled Analysis of Watch and Wait vs Total Mesorectal Excision in Patients With Rectal Cancer Who Respond to Total Neoadjuvant Therapy
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 07, 2025

    Expires: August 06, 2025

Provided by

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Exelixis, Inc., and Novartis Pharmaceuticals Corporation.

Boehringer Ingelheim Pharmaceuticals, Inc.

Exelixis, Inc.

Novartis Pharmaceuticals Corporation